FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1676-1680 April 19, 2007 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Roth, B. L. Related Article by Schade, R. Related Article by Zanettini, R. PubMed Citation

To the Editor: Schade et al. (Jan. 4 issue)¹ report an adjusted incidence-rate ratio of 4.9 for valvular regurgitation among patients taking the dopamine agonist cabergoline, especially at a daily dose above 3 mg and a duration of use of 6 months or more. The authors also report an incidence-rate ratio of 2.6 for cabergoline at a dose of 3 mg or less, adjusted for the cumulative duration of use. In the same issue, Zanettini et al.² report a relative risk of moderate or severe valvular regurgitation of 4.6 to 7.3 among patients taking cabergoline. They also describe a dose . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.